1. Adelaide Research & Scholarship

Search


Current filters:

Start a new search
Add filters:

Use filters to refine the search results.

 | 
Results 1-10 of 16 (Search time: 0.005 seconds).
Item hits:
PreviewIssue DateTitleAuthor(s)
1995A direct analysis of FACS-sorted hemopoietic cell fractions using fishWhite, D.; Hutchins, C.; Haylock, D.; Turczynowics, S.; Bishop, A.; To, L.; Hughes, T.; Juttner, C.
1997Mobilization of predominantly Philadelphia chromosome-negative blood progenitors using cyclophosphamide and rHUG-CSF in early chronic-phase chronic myeloid leukaemia: correlation with Sokal prognostic index and haematological control.Hughes, T.; Grigg, A.; Szer, J.; Ho, J.; Ma, D.; Dale, B.; Green, R.; Norman, J.; Sage, R.; Herrmann, R.; Cannell, P.; Schwarer, A.; Taylor, K.; Atkinson, K.; Arthur, C.
2014Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice dailyHughes, T.; Hochhaus, A.; Kantarjian, H.; Cervantes, F.; Guilhot, F.; Niederwieser, D.; Le Coutre, P.; Rosti, G.; Ossenkoppele, G.; Lobo, C.; Shibayama, H.; Fan, X.; Menssen, H.; Kemp, C.; Larson, R.; Saglio, G.
2016Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patientsDeininger, M.; Hodgson, J.; Shah, N.; Cortes, J.; Kim, D.; Nicolini, F.; Talpaz, M.; Baccarani, M.; Müller, M.; Li, J.; Parker, W.; Lustgarten, S.; Clackson, T.; Haluska, F.; Guilhot, F.; Kantarjian, H.; Soverini, S.; Hochhaus, A.; Hughes, T.; Rivera, V.; et al.
2015BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phaseHughes, T.; Saglio, G.; Quintás-Cardama, A.; Mauro, M.; Kim, D.; Lipton, J.; Bradley-Garelik, M.; Ukropec, J.; Hochhaus, A.
2011OCT-1 as a determinant of response to antileukemic treatmentEngler, J.; Hughes, T.; White, D.
2003Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemiaO'Brien, S.; Guilhot, F.; Larson, R.; Gathmann, I.; Baccarani, M.; Cervantes, F.; Cornelissen, J.; Fischer, T.; Hochhaus, A.; Hughes, T.; Lechner, K.; Nielsen, J.; Rousselot, P.; Reiffers, J.; Saglio, G.; Shepherd, J.; Simonsson, B.; Gratwohl, A.; Goldman, J.; Kantarjian, H.; et al.
2010Nilotinib versus Imatinib for newly diagnosed chronic myeloid leukemiaSaglio, G.; Kim, D.; Issaragrisil, S.; le Coutre, P.; Etienne, G.; Lobo, C.; Pasquini, R.; Clark, R.; Hochhaus, A.; Hughes, T.; Gallagher, N.; Hoenekopp, A.; Haque, A.; Dong, M.; Larson, R.; Kantarjian, H.
2012Rac2-MRC-cIII-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitorsNieborowska-Skorska, M.; Kopinski, P.; Ray, R.; Hoser, G.; Ngaba, D.; Flis, S.; Cramer, K.; Reddy, M.; Koptyra, M.; Penserga, T.; Glodkowska-Mrowka, E.; Bolton, E.; Holyoake, T.; Eaves, C.; Cerny-Reiterer, S.; Valent, P.; Hochhaus, A.; Hughes, T.; Van der Kuip, H.; Sattler, M.; et al.
2012BCR-ABL1 doubling times more reliably assess the dynamics of CML relapse compared with the BCR-ABL1 fold rise: implications for monitoring and managementBranford, S.; Yeung, D.; Prime, J.; Choi, S.; Bang, J.; Park, J.; Kim, D.; Ross, D.; Hughes, T.

Discover